Cargando…
Evaluating cost-effectiveness in the management of neuroendocrine neoplasms
The rapid evolution of novel, costly therapies for neuroendocrine neoplasia (NEN) warrants formal high-quality cost-effectiveness evaluation. Costs of individual investigations and therapies are high; and examples are presented. We aimed to review the last ten years of standalone health economic eva...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346405/ https://www.ncbi.nlm.nih.gov/pubmed/33155118 http://dx.doi.org/10.1007/s11154-020-09608-y |